{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"15.3","upperLimit":"84.7","value":"50.0"},{"groupId":"OG001","lowerLimit":"34.7","upperLimit":"62.9","value":"48.7"},{"groupId":"OG002","lowerLimit":"35.9","upperLimit":"62.0","value":"48.9"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"6"},{"groupId":"OG001","value":"39"},{"groupId":"OG002","value":"45"}],"units":"Participants"}],"description":"PFS rate was defined as the percentage of participants who were alive and have not had disease progression at 12 months after the date of first dose of treatment in Treatment Period I. PFS was assessed by International Myeloma Working Group (IMWG) Criteria (2014 version). Per IMWG criteria, progressive disease (PD): serum M-component increase ≥0.5 g/dl or urine M-component increase ≥200 mg/24-hour/ difference between involved and uninvolved free light chain (FLC) levels increase \\>10 mg/dl or bone marrow plasma cell ≥10%/ development of new/ increase in size of existing bone lesions or soft tissue plasmacytoma or development of hypercalcemia.","dispersionType":"90% Confidence Interval","groups":[{"description":"Bortezomib + Lenalidomide + Dexamethasone, standard recommended dose according to the package insert of each drug (Treatment Period I), followed by Ixazomib (4.0 mg) on Days 1, 8 and 15, plus Lenalidomide (25 mg) on Days 1 to 21, and Dexamethasone (40 mg) on Days 1, 8, 15 and 22, of a 28-day cycle (Treatment Period II)","id":"OG000","title":"[VRd]; Bortezomib + Lenalidomide + Dexamethasone Therapy"},{"description":"Carfilzomib + Lenalidomide + Dexamethasone, standard recommended dose according to the package insert of each drug (Treatment Period I), followed by Ixazomib (4.0 mg) on Days 1, 8 and 15, plus Lenalidomide (25 mg) on Days 1 to 21, and Dexamethasone (40 mg) on Days 1, 8, 15 and 22, of a 28-day cycle (Treatment Period II)","id":"OG001","title":"[KRd]; Carfilzomib + Lenalidomide + Dexamethasone Therapy"},{"description":"Bortezomib + Lenalidomide + Dexamethasone, or Carfilzomib + Lenalidomide + Dexamethasone, standard recommended dose according to the package insert of each drug (Treatment Period I), followed by Ixazomib (4.0 mg) on Days 1, 8 and 15, plus Lenalidomide (25 mg) on Days 1 to 21, and Dexamethasone (40 mg) on Days 1, 8, 15 and 22, of a 28-day cycle (Treatment Period II)","id":"OG002","title":"[Overall]; Combination Therapy + Ixazomib Therapy"}],"paramType":"NUMBER","populationDescription":"Full Analysis Set (FAS): all participants who were enrolled in Treatment Period I and who receive at least one dose of any therapy during the Treatment Period.","reportingStatus":"POSTED","timeFrame":"Up to 12 months","title":"Progression-Free Survival (PFS) Rate at 12 Months From the Start of Study Treatment","type":"PRIMARY","unitOfMeasure":"Percentage of Participants"}